In the Spotlight...

Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses

Building on prior evidence that anti-PD-1 and anti-CD47 antibodies can synergize by stimulating both the innate and adaptive immune systems and that tumor cells co-express both targets, Liu et al. developed a bispecific antibody (IAB) targeting both molecules. In vitro, IAB promoted T cell activation and macrophage phagocytosis. In an immunocompetent MC38 mouse model, intratumoral injection of IAB led to partial or complete antitumor responses in most mice. Both CD8+ T cells and macrophages contributed to the anti-tumor effect of IAB.

Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy

Barkal et al. discovered that a high level of expression of MHC class I molecules on the surface of tumor cells provides protection against phagocytosis by macrophages, mediated by interaction between the LILRB1 inhibitory receptor on the surface of macrophages and the β2-microglobulin component of the MHC class I molecule, independent of the MHC-I allele. Disrupting the MHC class I/LILRB1 axis, similar to disruption of the CD47/SIRPα axis, enhances phagocytosis of tumor cells in vitro and in vivo.

STAT5B: A Differential Regulator of the Life and Death of CD4(+) Effector Memory T Cells

To understand the mechanism underlying antigen restimulation-induced T cell death (RICD), a critical control to dampen T cell effector memory (TEM) levels, Majri et al. observed that STAT5B signaling drives RICD in TEM cells. A genetic screen of a patient with an autoimmune disorder revealed a missense mutation in the dimerization domain of STAT5B, causing lack of transcriptional activity. The patient’s CD4+ TEM cells were significantly increased and were highly resistant to cell death by in vitro TCR restimulation.

Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments

To reduce systemic side effects of alpha interferon but retain immune cell stimulating activity, Cauwels et al. constructed a mutated cytokine with >100x lower potency targeted to Clec9A+ cross-presenting dendritic cells (Clec9A-mAFN). In vivo, peri-tumoral Clec9A-mAFN stimulated Clec9A+ DCs in tumor-draining lymph nodes, controlled tumor growth in multiple models as well as full strength interferon but without toxicity, and synergized with other therapies, including checkpoint blockade. Activity depended on Batf3+ DCs and CD8+ T cells.

TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer

Byrd et al. engineered CAR T cells targeting TEM8, a marker on triple-negative breast cancer (TNBC), breast cancer stem-like cells (BCSCs), and tumor endothelial cells (TEC). The CAR T cells effectively killed TEC and TNBC cells and reduced the formation of mammospheres by BCSCs in vitro. In vivo, the CAR T cells induced regression of established cell line- and patient-derived xenograft tumors, disrupted tumor vascularization and infrastructure, blocked metastasis in xenograft tumors derived from a lung metastatic TNBC cell line, and improved survival.

An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors

Lu et al. developed a new approach to identify neoantigen-specific TCRs for use in adoptive T cell transfer. The process involves briefly co-culturing expanded tumor-infiltrating lymphocytes with autologous APCs that have been transfected with tandem minigenes containing patient-specific mutations or pulsed with mutant peptide, and using single-cell RNA sequencing to identify TCR sequences on activated T cells that express high levels of IFNγ and/or IL-2. A clinical trial to test this approach is being planned.

Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells

Sethumadhavan et al. discovered that hypoxia in the tumor microenvironment, and in 3D cultures, leads to decreased surface expression of MHC class I molecules by downregulating transcription of MHC class I heavy chains via the hypoxia-inducible factor (HIF) and by decreasing the levels of TAP1, TAP2, and LMP7, critical components of the antigen processing pathway. These results suggest that cancer immunotherapy may be improved by the addition of oxygenation or HIF inhibition.

Anti-SIRPalpha antibody immunotherapy enhances neutrophil and macrophage antitumor activity

Ring et al. developed KWAR23, an antibody that targets the SIRPα receptor on myeloid cells, to disrupt binding to the CD47 “don’t eat me” signal expressed on tumor (and normal) tissue to prevent macrophage phagocytosis. In combination with tumor-opsonizing antibodies, KWAR23 induced macrophages and neutrophils to phagocytose target tumor cells (from various tumor cell lines) in vitro. In human sirpa knock-in mice on an SRG background (lacking T, B, and NK cells), this combination elicited partial and complete responses.

Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response

Xue et al. used a single-cell microfluidics device to simultaneously measure 16 cytokines released by CD19 CAR T cells in response to target-specific stimulation, and developed two novel bioinformatics tools to visualize the data. CD19 CAR T cells exhibited a high degree of polyfunctionality (production of multiple cytokines, a predictor of therapeutic efficacy) dominated by antitumor effector and stimulatory functions, and significant heterogeneity, both within cells from the same donor and between donors.

PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis

In T cell non-Hodgkin lymphoma (NHL), oncogenic mutations to the TCR pathway induce chronic proliferation, however, Wartewig et al. found that PD-1 receptor-driven T cell inhibition suppresses oncogenic signaling in premalignant cells. In this context, total or hemizygous knockout of the PD-1 gene led to T cell hyperproliferation and rapid lymphomagenesis; treatment with anti-PD-1 antibodies led to lethal hyperproliferation, but the expanded cells were not lymphomagenic. Caution is warranted in employing checkpoint inhibition in T cell NHL.

Previous Digests

How our genes let the tumors get away

November 29, 2017

How does the immune system sculpt the tumor genome even before the tumor adapts counteracting immune evasion mechanisms? Marty et al. hypothesized that antigenic oncogenic mutations are eliminated by the immune system in the early stages of tumorigenesis, and this process is dependent on which oncogenic peptides can be effectively presented by an...

What’s in your gut? The gut microbiome influences the efficacy of anti-PD-1 immunotherapy

November 22, 2017

Responses to immunotherapy vary due to a number of factors, and according to two recent papers published in Science, the gut microbiome is definitely one of them. Both papers indicated that diversity of bacteria and the abundance of certain types of bacteria can affect patients’ response to anti-PD-1 immunotherapy for some cancer types...

What’s keeping natural killer cells in check?

November 15, 2017

In a recent paper published in Nature, Molgora et al. demonstrated that interleukin-1 receptor 8 (IL-1R8), which is a negative regulator of the IL-1 receptor (ILR) and Toll-like receptor (TLR) pathways, acts as a checkpoint for natural killer (NK) cell maturation and function, and removing this checkpoint could affect tumorigenesis and metastasis. Although...

About ACIR

ACIR's mission is to fast-track Cancer Immunotherapy Research by helping YOU to stay on top of the new literature in this fast-moving and multifaceted field, fostering YOUR creativity and productivity in bringing us ever closer to curing this deadly disease.

The work of ACIR and the Fritsch Foundation is so beautifully targeted on something that has the potential of being truly useful even in the earliest stages. What a great idea! " — John Petricciani, MD President of the International Alliance for Biological Standardization (IABS); Former Director of the Center for Biologics at FDA and former Chief Medical Officer of the Biologicals Unit at WHO
Our understanding of the interaction between the immune system and cancer cells, and also the ways to exploit this interaction clinically, is growing faster than ever before. At present, there is no reliable single source of information that can help clinicians and researchers in this field stay up-to-date, and by filling this gap, the Fritsch Foundation and initiative will facilitate the development of effective cancer immunotherapies for an increasing number of patient groups." — Ton Schumacher, PhD Deputy Director of the Netherlands Cancer Institute; Professor of Immunotechnology at Leiden University, The Netherlands; Chief Scientific Officer of Kite Pharma EU; SU2C-CRI Immunotherapy Dream Team member
Cancer Immunotherapy is providing patients with novel and durable treatments and the number of available therapies keeps growing. The mission of the Fritsch Foundation and its website—to accelerate the pace by which the field develops through mapping out the research and clinical landscapes and keeping track of key advances in the field—is an initiative that has my total support!! " — Robert D. Schreiber, PhD Alumni Endowed Professor of Pathology and Immunology and Professor of Molecular Microbiology at Washington University School of Medicine, MO; Director of the Washington University Center for Human Immunology and Immunotherapy Programs; Coleader of the Tumor Immunology Program of Washington University's Siteman Comprehensive Cancer Center; Associate Director of the Scientific Advisory Board to the Cancer Research Institute
I fully support the important new initiative of the Fritsch Foundation. The field of cancer immunotherapy grows at an exciting pace. Staying on top of foundational discoveries in the field, which will be conveniently processed on, is key for coming up with important new hypotheses about immunotherapeutic cancer treatment strategies." — Glenn Dranoff, MD, PhD Global Head of Immuno-Oncology, Novartis Institutes of BioMedical Research
I fully endorse the mission of the Fritsch Foundation and to provide a weekly synopsis of the scientific literature that bears on the field of cancer immunotherapy. The value and impact of this approach has been clearly demonstrated by a program I have been involved in as a member of the scientific advisory board of the Prize4Life Foundation, which is dedicated to curing the neurodegenerative disease ALS (Amyotrophic Lateral Sclerosis or Lou Gherig’s disease). ALS Forum, a joint effort between Prize4Life and the Alzheimer’s Research Forum provides ALS research summaries and well as links to ALS review articles as well as other content related to clinical trials. This program is widely used by the ALS research community to keep up to date with the rapidly moving scientific literature on ALS." — Tom Maniatis, PhD Chairman of the Department of Biochemistry and Molecular Biophysics at the Columbia University Medical Center (CUMC) in New York, and Director of the University wide Columbia Precision Medicine Initiative (CPMI)
The Fritsch Foundation and have identified a great way to meet the critical need of researchers and clinicians everywhere to stay up to date with the literature in the fast moving and life-saving field of cancer immunotherapy. This will be a fine living tribute to your son that has the potential to help many future cancer victims!" — James S. Economou, MD, PhD Beaumont Professor of Surgery, Microbiology, Immunology and Molecular Genetics, and Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA)
At a time when immunotherapy is being used for the treatment of increasing numbers of patients with cancer, there is a critical need to provide reliable information to patients, physicians and researchers. Key limitations to get to the reliable sources of information are the large amount of data that is being generated and published, the multiple clinical trials available and the differences in the ability of patients to access these therapies. Given these limitations, I welcome the efforts by The Fritsch Foundation and to make sense out of all this data and provide a reliable and timely source of information for the whole community of patients and researchers. They have full time scientists reviewing the data and pointing to the most important advances in the field of cancer immunotherapy." — Antoni Ribas, MD, PhD Professor of Medicine, Surgery, Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA); Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC); Director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA; Chair of the Melanoma Committee at SWOG